A BILL 
To amend the 21st Century Cures Act to reauthorize funding 
for FDA innovation projects, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Investing in Safety 
4
and Innovation Act of 2019’’. 
5
SEC. 
2. 
REAUTHORIZATION 
OF 
FDA 
INNOVATION 
6
PROJECTS. 
7
(a) TRANSFER OF DIRECT SPENDING SAVINGS.— 
8
Section 1002(b)(2)(A) of the 21st Century Cures Act 
9
(Public Law 114–255) is amended— 
10
01:07 Oct 12, 2019
H4633
2 
•HR 4633 IH
(1) in the matter preceding clause (i), by strik-
1
ing ‘‘2025’’ and inserting ‘‘2029’’; and 
2
(2) by striking clauses (iv) through (ix) and in-
3
serting the following: 
4
‘‘(iv) 
For 
fiscal 
year 
2020, 
5
$746,000,000. 
6
‘‘(v) 
For 
fiscal 
year 
2021, 
7
$551,000,000. 
8
‘‘(vi) For each of fiscal years 2022 
9
through 2024, $531,000,000. 
10
‘‘(vii) 
For 
fiscal 
year 
2025, 
11
$536,000,000. 
12
‘‘(viii) For each of fiscal years 2026 
13
through 2029, $531,000,000.’’. 
14
(b) FDA ACTIVITIES.—Paragraph (4) of section 
15
1002(b) of the 21st Century Cures Act (Public Law 114– 
16
255) is amended to read as follows: 
17
‘‘(4) FDA ACTIVITIES.—The activities author-
18
ized to be funded under this section shall consist of 
19
the following, and of the total amounts authorized to 
20
be appropriated under paragraph (3) there are au-
21
thorized to be appropriated to each category of ac-
22
tivities a total amount not to exceed the following: 
23
‘‘(A) In addition to the allocations speci-
24
fied in subparagraphs (B) through (K), for the 
25
01:07 Oct 12, 2019
H4633
3 
•HR 4633 IH
activities under subtitles A through F (includ-
1
ing the amendments made by such subtitles) of 
2
title III of this Act and section 1014 of the 
3
Federal Food, Drug, and Cosmetic Act, as 
4
added by section 3073 of this Act: 
5
‘‘(i) 
For 
fiscal 
year 
2020, 
6
$75,000,000. 
7
‘‘(ii) 
For 
fiscal 
year 
2021, 
8
$70,000,000. 
9
‘‘(iii) For each of fiscal years 2022 
10
through 2024, $50,000,000. 
11
‘‘(iv) 
For 
fiscal 
year 
2025, 
12
$55,000,000. 
13
‘‘(v) For each of fiscal years 2026 
14
through 2029, $50,000,000. 
15
‘‘(B) For modernization of the technical 
16
infrastructure of the Food and Drug Adminis-
17
tration, including enhancements such as inter-
18
operability across the agency, and additional ca-
19
pabilities to develop an advanced information 
20
technology infrastructure to support the agen-
21
cy’s regulatory mission: 
22
‘‘(i) 
For 
fiscal 
year 
2020, 
23
$300,000,000. 
24
01:07 Oct 12, 2019
H4633
4 
•HR 4633 IH
‘‘(ii) For each of fiscal years 2021 
1
through 2029, $200,000,000. 
2
‘‘(C) For support for continuous manufac-
3
turing of drugs and biological products, includ-
4
ing complex biological products such as regen-
5
erative medicine therapies, through grants to 
6
institutions of higher education and nonprofit 
7
organizations and other appropriate mecha-
8
nisms, for each of fiscal years 2020 through 
9
2029, $50,000,000. 
10
‘‘(D) For support for the Commissioner of 
11
Food and Drugs to engage experts, such as 
12
through the formation and operation of public- 
13
private partnerships or other appropriate col-
14
laborative efforts, to advance the development 
15
and delivery of individualized human gene ther-
16
apy products: 
17
‘‘(i) 
For 
fiscal 
year 
2020, 
18
$50,000,000. 
19
‘‘(ii) For each of fiscal years 2021 
20
through 2029, $10,000,000. 
21
‘‘(E) For support for inspections and en-
22
forcement activities across the Food and Drug 
23
Administration, including foreign and domestic 
24
01:07 Oct 12, 2019
H4633
5 
•HR 4633 IH
facility inspections across products, for each of 
1
fiscal years 2020 through 2029, $82,500,000. 
2
‘‘(F) For support for activities of the Food 
3
and Drug Administration related to customs 
4
and border protection to provide improvements 
5
to technologies, inspection capacity, and inter-
6
national mail facilities in which the Food and 
7
Drug Administration operates, for each of fiscal 
8
years 2020 through 2029, $25,000,000. 
9
‘‘(G) To further advance the development 
10
of a coordinated postmarket surveillance system 
11
for all medical products, including drugs, bio-
12
logical products, and devices, linked to elec-
13
tronic health records in furtherance of the Food 
14
and Drug Administration’s postmarket surveil-
15
lance capabilities: 
16
‘‘(i) 
For 
fiscal 
year 
2020, 
17
$100,000,000. 
18
‘‘(ii) For each of fiscal years 2021 
19
through 2029, $50,000,000. 
20
‘‘(H) For support for Food and Drug Ad-
21
ministration activities to keep pace with the 
22
projected product development of regenerative 
23
therapies, including human somatic cellular and 
24
01:07 Oct 12, 2019
H4633
6 
•HR 4633 IH
gene therapies, for each of fiscal years 2020 
1
through 2029, $25,000,000. 
2
‘‘(I) For support for the development of 
3
non-opioid pharmacological therapies as alter-
4
natives for opioids, for each of fiscal years 2020 
5
through 2029, $3,500,000. 
6
‘‘(J) For carrying out section 714A of the 
7
Federal Food, Drug, and Cosmetic Act (21 
8
U.S.C. 379d–3a; relating to hiring authority for 
9
scientific, technical, and professional personnel), 
10
for each of fiscal years 2020 through 2029, 
11
$20,000,000. 
12
‘‘(K) For the Food and Drug Administra-
13
tion to support improvements to the techno-
14
logical infrastructure for reporting and analysis 
15
of adverse events associated with the use of 
16
drugs and biological products, for each of fiscal 
17
years 2020 through 2029, $15,000,000.’’. 
18
(c) ANNUAL REPORTS.—Section 1002(c)(2)(A) of the 
19
21st Century Cures Act (Public Law 114–255) is amend-
20
ed by striking ‘‘2026’’ and inserting ‘‘2029’’. 
21
(d) SUNSET.—Section 1002(e) of the 21st Century 
22
Cures Act (Public Law 114–255) is amended by striking 
23
01:07 Oct 12, 2019
H4633
7 
•HR 4633 IH
‘‘September 30, 2026’’ and inserting ‘‘September 30, 
1
2029’’. 
2
Æ 
01:07 Oct 12, 2019
H4633
